pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$HRTXHERON THERAPEUTICS, INC. /DE/

$HRTX0.5114+3.06%
San Diego, CA, USupdated 17d ago
SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
1
marketed
0
phase 3
0
catalysts ytd
2
approvals ytd
1
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Unknown: 1
1Unknown
drug
SUSTOL
1 INDICATIONS AND USAGE SUSTOL is indicated in combinatio…
5-hydroxytryptamine receptor 3A

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →

Active trials

  • phase2Pilot Herniorrhaphy Study for Postoperative Analgesiacompletedn=463
  • phase2Phase 2B Upper Extremity Nerve Block Studycompletedn=243
  • phase3Phase 3 Herniorrhaphy Study for Postoperative Analgesia (EPOCH 2)completedn=418
  • phase3APF530 or Aloxi (Palonosetron Hydrochloride) Combined With Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Cancercompletedn=1,428
  • phase2Total Knee Arthroplasty Infiltration Study for Postoperative Analgesiacompletedn=285
  • phase2Phase 2 Herniorrhaphy Study for Opioid Eliminationcompletedn=63
  • phase3A Prospective, Multicenter, Study of APF530 (Granisetron) SC for Prevention of CINV in Patients Receiving HECcompletedn=942
  • phase3Total Knee Arthroplasty (TKA) Study of HTX-011 in an Multimodal Analgesic Regimen (MMA) Regimencompletedn=116
more trials →

Insider activity

source: SEC Form 4
routine RSU / option mechanics (6)
  • Apr 19, 26option exerciseForbes William P · EVP, Chief Development Officer3,874 sh
  • Apr 19, 26option exerciseForbes William P · EVP, Chief Development Officer3,874 sh
  • Apr 19, 26option exerciseCollard Craig A · Chief Executive Officer13,797 sh
  • Apr 19, 26option exerciseCollard Craig A · Chief Executive Officer13,797 sh
  • Apr 19, 26option exerciseDuarte Ira · EVP, Chief Financial Officer3,874 sh
  • Apr 19, 26option exerciseDuarte Ira · EVP, Chief Financial Officer3,874 sh
🐶 Hiring Signal
No open roles indexed yet — view HERON THERAPEUTICS, INC. /DE/ jobs →

News

no news has mentioned this company yet
identifiers
ticker
$HRTX
SEC CIK
0000818033
country
US
source
sec_tickers
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR · openFDA
last refreshed 18m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?